None
SEDAR Interim Financial Statements
QPT · Price
[
{
"companyName": "Quest PharmaTech Inc.",
"reportingPeriodEnd": "2025-10-31",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 58241,
"prepaidExpenses": 25463,
"totalCurrentAssets": 83704,
"prepaidExpensesNonCurrent": 5855,
"investmentInOncoQuest": 6519553,
"investmentInOqpBioBondsAndOqpbiomShares": 17724160,
"totalNonCurrentAssets": 24249568,
"totalAssets": 24333272,
"accountsPayablesAndAccruedLiabilities": 253864,
"shortTermLoan": 1000000,
"totalLiabilities": 1253864,
"commonShares": 30741316,
"contributedSurplus": 11768581,
"accumulatedDeficit": -19285848,
"accumulatedOtherComprehensiveLoss": -144641,
"totalShareholdersEquity": 23079408,
"totalLiabilitiesAndShareholdersEquity": 24333272,
"cashPerShare": 0.0003,
"workingCapitalPerShare": -0.0069
},
"incomeStatement": {
"threeMonthsEndedOct312025": {
"generalAndAdministrative": 180703,
"researchAndDevelopment": 59874,
"totalExpenses": 240577,
"operatingLoss": -240577,
"equityLossIncomeOncoQuest": 1249199,
"costRecovery": 75000,
"foreignExchangeGainLoss": 1,
"financeExpenses": -5105,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": null,
"totalOtherIncome": 1319095,
"incomeLossBeforeIncomeTax": 1078518,
"incomeTaxRecoveryExpense": null,
"netIncomeLoss": 1078518,
"otherComprehensiveIncomeLoss": 6550,
"netAndComprehensiveIncomeLoss": 1085068,
"incomeLossPerShareBasicAndDiluted": 0.0064,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 169129247
},
"threeMonthsEndedOct312024": {
"generalAndAdministrative": 142559,
"researchAndDevelopment": 102750,
"totalExpenses": 245309,
"operatingLoss": -245309,
"equityLossIncomeOncoQuest": -63173,
"costRecovery": 75000,
"foreignExchangeGainLoss": 4,
"financeExpenses": -10367,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": 278574,
"totalOtherIncome": 280038,
"incomeLossBeforeIncomeTax": 34729,
"incomeTaxRecoveryExpense": null,
"netIncomeLoss": 34729,
"otherComprehensiveIncomeLoss": -3625,
"netAndComprehensiveIncomeLoss": 31104,
"incomeLossPerShareBasicAndDiluted": 0.0002,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 169129247
},
"nineMonthsEndedOct312025": {
"generalAndAdministrative": 333312,
"researchAndDevelopment": 180879,
"totalExpenses": 514191,
"operatingLoss": -514191,
"equityLossIncomeOncoQuest": 1218138,
"costRecovery": 225000,
"foreignExchangeGainLoss": -2618,
"financeExpenses": -15287,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": 686381,
"totalOtherIncome": 2111614,
"incomeLossBeforeIncomeTax": 1597423,
"incomeTaxRecoveryExpense": null,
"netIncomeLoss": 1597423,
"otherComprehensiveIncomeLoss": 6830,
"netAndComprehensiveIncomeLoss": 1604253,
"incomeLossPerShareBasicAndDiluted": 0.0094,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 169129247
},
"nineMonthsEndedOct312024": {
"generalAndAdministrative": 312448,
"researchAndDevelopment": 227681,
"totalExpenses": 540129,
"operatingLoss": -540129,
"equityLossIncomeOncoQuest": -384695,
"costRecovery": 225000,
"foreignExchangeGainLoss": -1621,
"financeExpenses": -22523,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": 616933,
"totalOtherIncome": 433094,
"incomeLossBeforeIncomeTax": -107035,
"incomeTaxRecoveryExpense": null,
"netIncomeLoss": -107035,
"otherComprehensiveIncomeLoss": -7709,
"netAndComprehensiveIncomeLoss": -114744,
"incomeLossPerShareBasicAndDiluted": -0.0006,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 169129247
}
},
"cashFlowStatement": {
"threeMonthsEndedOct312025": {
"netIncomeLoss": 1078518,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": null,
"shareBasedPayments": 80000,
"equityIncomeLossOncoQuest": -1249199,
"otherReceivables": null,
"prepaidExpenses": -20401,
"accountsPayablesAndAccruedLiabilities": 76083,
"netCashUsedInOperatingActivities": -34999,
"netCashUsedInInvestingActivities": null,
"netCashProvidedByFinancingActivities": null,
"changeInCash": -34999,
"cashBeginningOfPeriod": 93240,
"cashEndOfPeriod": 58241
},
"threeMonthsEndedOct312024": {
"netIncomeLoss": 34729,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": -278574,
"shareBasedPayments": 84000,
"equityIncomeLossOncoQuest": 63173,
"otherReceivables": -25000,
"prepaidExpenses": -23099,
"accountsPayablesAndAccruedLiabilities": 9696,
"netCashUsedInOperatingActivities": -135075,
"netCashUsedInInvestingActivities": null,
"netCashProvidedByFinancingActivities": null,
"changeInCash": -135075,
"cashBeginningOfPeriod": 321431,
"cashEndOfPeriod": 186356
},
"nineMonthsEndedOct312025": {
"netIncomeLoss": 1597423,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": -686381,
"shareBasedPayments": 80000,
"equityIncomeLossOncoQuest": -1218138,
"otherReceivables": null,
"prepaidExpenses": -5269,
"accountsPayablesAndAccruedLiabilities": 85521,
"netCashUsedInOperatingActivities": -146844,
"netCashUsedInInvestingActivities": null,
"netCashProvidedByFinancingActivities": null,
"changeInCash": -146844,
"cashBeginningOfPeriod": 205085,
"cashEndOfPeriod": 58241
},
"nineMonthsEndedOct312024": {
"netIncomeLoss": -107035,
"fairValueAdjustmentInInvestmentInOqpBioBondsAndShares": -616933,
"shareBasedPayments": 84000,
"equityIncomeLossOncoQuest": 384695,
"otherReceivables": -25000,
"prepaidExpenses": -9192,
"accountsPayablesAndAccruedLiabilities": -241142,
"netCashUsedInOperatingActivities": -530607,
"netCashUsedInInvestingActivities": null,
"netCashProvidedByFinancingActivities": null,
"changeInCash": -530607,
"cashBeginningOfPeriod": 716963,
"cashEndOfPeriod": 186356
}
},
"investmentsAndOtherAssets": [
{
"type": "Equity Investment",
"description": "Investment in OncoQuest Inc.",
"ownershipPercentage": 42.52,
"value": 6519553,
"notes": "Private Canadian biotechnology company developing next generation of combinatorial immunotherapy products for the treatment of cancer."
},
{
"type": "Equity Investment",
"description": "Investment in OQPBIOM Inc. shares",
"ownershipPercentage": 26,
"value": 17724160,
"notes": "Private Korean company that owns immunotherapy assets and is developing immunotherapeutic products for the treatment of cancer. Converted from bonds in April 2025."
},
{
"type": "Equity Investment",
"description": "Investment in OncoVent Co., Ltd.",
"ownershipPercentage": 11,
"value": null,
"notes": "Joint venture in China focusing on research and development of Cancer Immunotherapy Products for the Chinese market."
}
],
"shareStructure": {
"authorizedShares": "Unlimited number of common shares, first preferred shares, and second preferred shares",
"issuedShares": 169129247,
"classesOfShares": ["common", "first preferred", "second preferred"],
"warrants": [],
"options": [
{
"number": 1550000,
"exercisePrice": 0.08,
"expiryDate": null
},
{
"number": 1200000,
"exercisePrice": 0.09,
"expiryDate": null
},
{
"number": 4350000,
"exercisePrice": 0.10,
"expiryDate": null
},
{
"number": 2050000,
"exercisePrice": 0.115,
"expiryDate": null
},
{
"number": 2725000,
"exercisePrice": 0.15,
"expiryDate": null
},
{
"number": 1150000,
"exercisePrice": 0.18,
"expiryDate": null
},
{
"number": 1720000,
"exercisePrice": 0.23,
"expiryDate": null
},
{
"number": 1560000,
"exercisePrice": 0.25,
"expiryDate": null
},
{
"number": 4800000,
"exercisePrice": 0.05,
"expiryDate": null
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"threeMonthsEndedOct312025": {
"managementFees": 76555,
"totalCompensation": 76555
},
"threeMonthsEndedOct312024": {
"managementFees": 64767,
"totalCompensation": 64767
},
"nineMonthsEndedOct312025": {
"managementFees": 190326,
"totalCompensation": 190326
},
"nineMonthsEndedOct312024": {
"managementFees": 178538,
"totalCompensation": 178538
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "OncoQuest Inc.",
"description": "Executive Services Agreement - cost recovery",
"amount": 75000,
"period": "Three months ended October 31, 2025"
},
{
"counterparty": "OncoQuest Inc.",
"description": "Executive Services Agreement - cost recovery",
"amount": 75000,
"period": "Three months ended October 31, 2024"
},
{
"counterparty": "OncoQuest Inc.",
"description": "Executive Services Agreement - cost recovery",
"amount": 225000,
"period": "Nine months ended October 31, 2025"
},
{
"counterparty": "OncoQuest Inc.",
"description": "Executive Services Agreement - cost recovery",
"amount": 225000,
"period": "Nine months ended October 31, 2024"
},
{
"counterparty": "OncoQuest Inc.",
"description": "Short term loan - unsecured, 2% interest bearing, repayable on demand",
"amount": 1000000,
"period": "Outstanding as at October 31, 2025"
}
]
},
"subsequentEvents": []
}
]